April 29 Quick Takes: Takeda, Emendo, ViiV, Zynquista, Benlysta and more

Takeda considering value-based pricing in EU
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) is mulling employing a value-based pricing model in Europe for Alofisel darvadstrocel, a stem cell therapy to treat complex perianal fistulas in patients with Crohn’s disease, Chief Medical and Scientific Officer Andrew Plump told BioCentury.

Emendo grants Takeda option to gene editing platform
Emendo Biotherapeutics Inc. (New York, N.Y.) granted Takeda an option to use Emendo's OMNI nuclease gene editing program to edit two genes for R&D purposes. Emendo will receive an undisclosed investment from Takeda Ventures in the form of notes that will be converted in the biotech's planned series B...